Sylvain Celanire, PhD

Sylvain has served as first CEO of Augustine Therapeutics, building the team, establishing R&D operations along setting wet-labs and offices in Leuven. He successfully raised a total of €20m in Seed and Series A1 financing rounds along €2m in non dilutive fundings from US patient advocacy groups and government organizations. He has discovered and promoted AGT-100216 as the first clinical candidate of Augustine TX HDAC6i portfolio, currently in Phase 1 trial. Prior to joining Augustine, he was the Co-Founder and CEO of Pragma Therapeutics, a French neuroscience biotech company. Sylvain has also held a number of roles of increasing responsibility and seniority in mid-size biopharma companies, including as Group Leader and Research Director in Medicinal Chemistry (CNS) at Addex Therapeutics (CH), managing research collaboration with Merck&Co/-US, as well as Principal Scientist at UCB Pharma (BE). Sylvain recerived his PhD in organic and medicinal chemistry from the Univeristy of Rouen, France. He completed two industry-funded Postdoctoral Fellowships, the most recent in organic chemistry from the University of Oxford, UK in 2002.